Moss Genomics, Inc.
0.02
CAD
+0.01
(+50.00%)
Moss Genomics, Inc.
CSE:MOSS
(Canadian Securities Exchange)
Recent
price
0.02
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.- Similar Companies
- Business
- Moss Genomics, Inc. is a biotechnology and digital health company that provides personalized genomic and microbiome testing solutions integrated with health intelligence software and blockchain-secured data management infrastructure. The company operates through core business segments encompassing consumer health diagnostics, personalized nutrition, and decentralized health data management. Its primary product and service offerings comprise direct-to-consumer and clinical-grade at-home gut microbiome and genetic testing kits; the Perennial health intelligence platform, which aggregates and analyzes laboratory diagnostic results, genomic sequences, and biometric data from wearable devices to deliver personalized dietary, wellness, and lifestyle recommendations; custom-formulated probiotic and nutritional dietary supplements; and encrypted genomic data vault solutions that utilize decentralized blockchain architecture to facilitate secure patient data storage, pay-per-genome research access, and sovereign data monetization. Moss Genomics serves individual consumers, wellness practitioners, and biomedical research institutions across North America and select international markets. Founded in 2018 under the predecessor name Nou Camp Capital Corp. before rebranding to Moss Genomics Inc. in July 2021, the company is headquartered in Vancouver, British Columbia, Canada. In recent corporate developments, Moss Genomics launched its proprietary Perennial health intelligence platform in April 2025 and entered into a strategic collaboration memorandum of understanding with Proteic in February 2025 to design novel protein structures for commercial dietary supplements. In June 2025, the company completed a strategic investment in Genomes.io Ltd., a United Kingdom-based decentralized genomic data platform, to enhance its secure genomic infrastructure. Strategically, following the appointment of Jack Liu as Chief Executive Officer in December 2024, the company instituted a corporate digital asset treasury reserve strategy, participated in decentralized smart contract protocol allocations, and expanded its computational infrastructure into Bitcoin Cash network mining in January 2026. Furthermore, Moss Genomics expanded its international capital markets presence by dual-listing on the Frankfurt Stock Exchange under the ticker symbol F73 in January 2025, completed private placement financings in November 2025, and initiated continuous disclosure reporting remediation with the British Columbia Securities Commission in August 2026.